Long-form articles on therapeutic virtual reality, written for clinicians. Applicable in your practice tomorrow. No marketing speak.
What the meta-analyses report on the efficacy of exposure therapy: effect sizes by comparator, maintenance at follow-up and the honest limits of the evidence.
What VRET is, the clinical evidence (Cochrane meta-analyses, UJI research), building a VR exposure hierarchy, contraindications, and ROI for private practice.
How the NHS's gameChange trial paired VR exposure with an automated virtual coach to treat severe agoraphobia — and what it means for private practice.
A clinical review of EMDR and VR for trauma: the AIP model, bilateral stimulation inside virtual environments and an honest look at thin evidence.
A ten-year forecast for VR exposure therapy as first-line phobia treatment: research funding, regulation and the adoption trends clinics should watch.
A data-driven look at VR exposure therapy adoption in Spanish clinics in 2026: usage rates, the barriers slowing growth, and what NHS and CleVR signal ahead.
How Jeffrey Gray's behavioral inhibition system (BIS) explains OCD avoidance, and how virtual reality can help structure exposure and response prevention (ERP).
How Barlow's tripartite vulnerability model explains why VR exposure activates the same conditioned-fear mechanisms, and why presence is the key.
Immersion is a property of the system, presence is the patient's response: how to measure it with IPQ and MEC-SPQ, and why headset quality matters.
Why VR exposure sees lower dropout than in-vivo therapy: the psychology of perceived control, fine-grained gradation, and documented patient preference.
Powers and Emmelkamp, Opriş and Carl compared: VRET effect sizes against in vivo exposure for anxiety and phobias, with their methodological limits.